- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Access program opened for investigational AIDS drug
Tibotec Pharmaceuticals has announced the opening of an expanded-access program for TMC125, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1.
Tibotec Pharmaceuticals has announced the opening of an expanded-access program for TMC125, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1. The compound is currently in phase III trials and is active against NNRTI-resistant strains of the virus. The program is available to patients with HIV-1 who are at least 18 years old, have a history of virological failure or intolerance to previous regimens, and have received treatment from each of the three major oral classes of drugs (nucleoside reverse transcriptase inhibitor, NNRTIs, and protease inhibitors), with at least two being protease inhibitor-based regimens. For more information about the program, call 1-(866) 889-2074.
Pharmaceutical Compounding, Storage of Faricimab Preserves Stability, Binding Properties
November 28th 2023Maintaining the structure and function of antibody biologics like faricimab is critical for their administration via intravitreal injection (IVI), a common treatment approach for retinal diseases.
